Posted by Michael Wonder on 29 Mar 2025
FDA approves novel treatment for haemophilia A or B, with or without factor inhibitors
28 March 2025 - Medication can be given up to once every 2 months.
Today, the US FDA approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and paediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralising antibodies).
